Previous 10 | Next 10 |
home / stock / envb / envb articles
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded down 0.16% to 38,8...
Enveric Biosciences, Inc. (NASDAQ:ENVB) shares are soaring Thursday after the company announced it has signed three non-binding term sheets with an...
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursd...
Enveric Biosciences Inc. (NASDAQ:ENVB) said on Friday it has agreed to sell one of its cancer-related patent portfolios. The Cambridge, Massachuset...
Enveric Biosciences (NASDAQ:ENVB) announced the discovery of multiple compounds sourced using its Psybrary platform and proprietary computatio...
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substance...
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Results of a first-in-class clinical trial on ibogaine-magnesium th...
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Results of a first-in-class clinical trial on ibogaine-magnesium th...
News, Short Squeeze, Breakout and More Instantly...
Enveric Biosciences Inc Com Company Name:
ENVB Stock Symbol:
NASDAQ Market:
Enveric Biosciences Inc Com Website:
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025 ...
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Com...